Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 16:07 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Reports Third Quarter 2025 Results

Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the third quarter and nine months ended Sept. 30, 2025.
November 03, 2025 16:05 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

today announced the launch of AdvanceAD-Tx™, a GEP test designed to guide systemic treatment decision making in patients ages 12 and older.
October 28, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences to Participate in Upcoming Investor Conferences

Castle Biosciences to Participate in November Investor Conferences
October 26, 2025 15:05 ET | Source: Castle Biosciences, Inc.

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus

Castle announced new data on its TissueCypher® Barrett’s Esophagus test being presented at ACG 2025.
October 24, 2025 04:05 ET | Source: Castle Biosciences, Inc.

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Castle is presenting data on DecisionDx®-Melanoma and its pipeline atopic dermatitis (AD) test at the 25th Annual Fall Clinical Dermatology Conference.
October 13, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

Castle Biosciences will release Q3 2025 financial results and host conference call on Monday, Nov. 3, 2025
October 01, 2025 16:30 ET | Source: Castle Biosciences, Inc.

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

Castle Biosciences' Founder, President & CEO Derek Maetzold awarded CEO of the Year by The CEO Magazine
September 23, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award

Castle Biosciences has been recognized as a Greater Pittsburgh Top Workplace by The Pittsburgh Post-Gazette
September 17, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025

Castle Biosciences has been included in the inaugural 2025 America’s Greatest Companies list, published by Newsweek.
September 09, 2025 07:00 ET | Source: Castle Biosciences, Inc.

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

Castle will share new data on its TissueCypher Barrett’s Esophagus test via a podium presentation on Sept. 13 at the AFS 2025 Annual Meeting.